COL7A1 and recessive dystrophic epidermolysis bullosa: The results comparable in safety and initial efficacy were obtained by Lwin S. et al. (2019), who conducted a phase I clinical trial (NCT02493816) with the participation of four adult RDEB patients who received three intradermal injections of autoDFs modified with COL7A1 in intact skin areas [65].